An Immune Relevant Signature for Predicting Prognoses and Immunotherapeutic Responses in Patients with Muscle-invasive Bladder Cancer (MIBC)

Overview

Journal Cancer Med

Specialty Oncology

Date 2020 Feb 26

PMID 32096345

Citations 41

Authors

Wen Jiang

Dandan Zhu

Chenghe Wang

Yu Zhu

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) are novel treatments that significantly improve the survival time of MIBC patients, but immunotherapeutic responses are different among MIBC patients. Therefore, it is urgent to find predictive biomarkers that can accurately identify MIBC patients who are sensitive to ICIs. In this study, we computed the relative abundances of 24 immune cells based on the expression profiles of MIBC patients using single-sample gene set enrichment analysis (ssGSEA). Unsupervised clustering analysis of the 24 immune cells was performed to classify MIBC patients into different immune-infiltrating groups. Genome (gene mutation and copy number variation), transcriptome (mRNA, lncRNA, and miRNA), and functional enrichment were found to be heterogeneous among different immune-infiltrating groups. We identified 282 differentially expressed genes (DEGs) associated with immune infiltration by comparing the expression profiles of patients with different immune infiltration profiles, and 20 core prognostic DEGs were identified by univariate Cox regression analysis. An immune-relevant gene signature (TIM signature) consisting of nine key prognostic DEGs (CCDC80, CD3D, CIITA, FN1, GBP4, GNLY, SPINK1, UBD, and VIM) was constructed using least absolute shrinkage and selection operator (LASSO) Cox regression analysis. Receiver operating characteristic (ROC) curves and subgroup analysis confirmed that the TIM signature was an ideal biomarker for predicting the prognosis of MIBC patients. Its value in predicting immunotherapeutic responses was also validated in The Cancer Genome Atlas (TCGA) cohort (AUC = 0.69, 95% CI = 0.63-0.74) and the IMvigor210 cohort (AUC = 0.64, 95% = 0.55-0.74). The TIM signature demonstrates a powerful ability to distinguish MIBC patients with different prognoses and immunotherapeutic responses, but more prospective studies are needed to assess its reliability in the future.

Citing Articles

Prediction of bladder cancer prognosis and immune microenvironment assessment using machine learning and deep learning models.

Nie W, Jiang Y, Yao L, Zhu X, Al-Danakh A, Liu W Heliyon. 2024; 10(23):e39327.

PMID: 39687145 PMC: 11647853. DOI: 10.1016/j.heliyon.2024.e39327.

Prediction of immunotherapy response of bladder cancer with a pyroptosis-related signature indicating tumor immune microenvironment.

Xu Z, Zhao Y, Zhang Y, Liu X, Song L, Chen M Front Pharmacol. 2024; 15:1387647.

PMID: 38983908 PMC: 11231188. DOI: 10.3389/fphar.2024.1387647.

Silencing immune-infiltrating biomarker CCDC80 inhibits malignant characterization and tumor formation in gastric cancer.

Yu M, Peng J, Lu Y, Li S, Ding K BMC Cancer. 2024; 24(1):724.

PMID: 38872096 PMC: 11170897. DOI: 10.1186/s12885-024-12451-y.

Transcriptome Analysis Reveals Distinct Patterns Between the Invasive and Noninvasive Pituitary Neuroendocrine Tumors.

Jotanovic J, Tebani A, Hekmati N, Sivertsson A, Lindskog C, Uhlen M J Endocr Soc. 2024; 8(5):bvae040.

PMID: 38505563 PMC: 10949357. DOI: 10.1210/jendso/bvae040.

Single-Cell Sequencing Combined with Transcriptome Sequencing Constructs a Predictive Model of Key Genes in Multiple Sclerosis and Explores Molecular Mechanisms Related to Cellular Communication.

Hu F, Zhu Y, Tian J, Xu H, Xue Q J Inflamm Res. 2024; 17:191-210.

PMID: 38226354 PMC: 10788626. DOI: 10.2147/JIR.S442684.

References

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Finotello F, Trajanoski Z . Quantifying tumor-infiltrating immune cells from transcriptomics data. Cancer Immunol Immunother. 2018; 67(7):1031-1040. PMC: 6006237. DOI: 10.1007/s00262-018-2150-z. View

Tunger A, Sommer U, Wehner R, Kubasch A, Grimm M, Bachmann M . The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. J Clin Med. 2019; 8(10). PMC: 6832659. DOI: 10.3390/jcm8101534. View

Stelekati E, Chen Z, Manne S, Kurachi M, Ali M, Lewy K . Long-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155. Cell Rep. 2018; 23(7):2142-2156. PMC: 5986283. DOI: 10.1016/j.celrep.2018.04.038. View

Bellmunt J, Powles T, Vogelzang N . A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treat Rev. 2017; 54:58-67. DOI: 10.1016/j.ctrv.2017.01.007. View

Carosella E, Ploussard G, LeMaoult J, Desgrandchamps F . A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015; 68(2):267-79. DOI: 10.1016/j.eururo.2015.02.032. View

Pettenati C, Ingersoll M . Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018; 15(10):615-625. DOI: 10.1038/s41585-018-0055-4. View

Sun Y, Oravecz-Wilson K, Mathewson N, Wang Y, McEachin R, Liu C . Mature T cell responses are controlled by microRNA-142. J Clin Invest. 2015; 125(7):2825-40. PMC: 4563679. DOI: 10.1172/JCI78753. View

Redelman-Sidi G, Glickman M, Bochner B . The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol. 2014; 11(3):153-62. DOI: 10.1038/nrurol.2014.15. View

10.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

11.

Locy H, de Mey S, de Mey W, De Ridder M, Thielemans K, Maenhout S . Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend. Front Immunol. 2019; 9:2909. PMC: 6297829. DOI: 10.3389/fimmu.2018.02909. View

12.

Giridhar K, Kohli M . Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer. Mayo Clin Proc. 2017; 92(10):1564-1582. DOI: 10.1016/j.mayocp.2017.07.010. View

13.

Smith J, Sheltzer J . Systematic identification of mutations and copy number alterations associated with cancer patient prognosis. Elife. 2018; 7. PMC: 6289580. DOI: 10.7554/eLife.39217. View

14.

Pfannstiel C, Strissel P, Chiappinelli K, Sikic D, Wach S, Wirtz R . The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. Cancer Immunol Res. 2019; 7(6):923-938. DOI: 10.1158/2326-6066.CIR-18-0758. View

15.

Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S . A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012; 18(12):3377-86. DOI: 10.1158/1078-0432.CCR-12-0077-T. View

16.

Liu Q, Zhang M, Jiang X, Zhang Z, Dai L, Min S . miR-223 suppresses differentiation of tumor-induced CD11b⁺ Gr1⁺ myeloid-derived suppressor cells from bone marrow cells. Int J Cancer. 2011; 129(11):2662-73. DOI: 10.1002/ijc.25921. View

17.

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

18.

Kapsogeorgou E, Papageorgiou A, Protogerou A, Voulgarelis M, Tzioufas A . Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjögren's syndrome. Ann Rheum Dis. 2018; 77(8):1200-1207. DOI: 10.1136/annrheumdis-2017-212639. View

19.

Zheng Z, Sun R, Zhao H, Fu D, Zhong H, Weng X . MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells. Mol Cancer. 2019; 18(1):54. PMC: 6441197. DOI: 10.1186/s12943-019-0977-3. View

20.

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F . Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2016; 71(1):96-108. DOI: 10.1016/j.eururo.2016.06.010. View